Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease

Nutrients

Volumn 5, Issue 6, 2013, Pages 1913-1936

  Tejwani, Vickram ^a   Qian, Qi ^a  

^a Mayo Clinic   (United States)

Author keywords

Aging; Calcium homeostasis; Chronic kidney disease; Mineral and bone disorder; Secondary hyperparathyroidism; Vascular calcification

Indexed keywords

CALCIUM ION; CALCIUM PHOSPHATE; CALCIUM SENSING RECEPTOR; CINACALCET; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; VITAMIN D;

AGED; AGING; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MECHANISM; FOOD COMPOSITION; FRACTURE; GLOMERULUS FILTRATION RATE; GOLD STANDARD; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; REVIEW; SECONDARY HYPERPARATHYROIDISM; TRABECULAR BONE; VITAMIN D DEFICIENCY;

EID: 84878431459     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu5061913     Document Type: Review

References (157)

1. World Population Prospects: The 2010 Revision, Volume I: Comprehensive Tables; United Nations Department of Economic and Social Affairs Population Division: New York, NY, USA, 2011.
2. Peacock, M. Calcium metabolism in health and disease. Clin. J. Am. Soc. Nephrol. 2010, 5, S23-S30.
3. Koeppen, B.M.; Stanton, B.A. Renal Physiology, 5th ed.; Elsevier: Philadelphia, PA, USA; p. 240.
4. Hebert, S.C. Calcium and salinity sensing by the thick ascending limb: A journey from mammals to fish and back again. Kidney Int. Suppl. 2004, 91, S28-S33.
5. Hebert, S.C.; Brown, E.M.; Harris, H.W. Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. J. Exp. Biol. 1997, 200, 295-302.
6. Hou, J.; Rajagopal, M.; Yu, A.S. Claudins and the Kidney. Annu. Rev. Physiol. 2013, 75, 479-501.
7. Vennekens, R.; Hoenderop, J.G.; Prenen, J.; Stuiver, M.; Willems, P.H.; Droogmans, G.; Nilius, B.; Bindels, R.J. Permeation and gating properties of the novel epithelial Ca(2+) channel. J. Biol. Chem. 2000, 275, 3963-3969.
8. Chang, Q.; Hoefs, S.; van der Kemp, A.W.; Topala, C.N.; Bindels, R.J.; Hoenderop, J.G. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005, 310, 490-493.
9. Cha, S.K.; Ortega, B.; Kurosu, H.; Rosenblatt, K.P.; Kuro-o, M.; Huang, C.L. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc. Natl. Acad. Sci. USA 2008, 105, 9805-9810.
10. Blankenship, K.A.; Williams, J.J.; Lawrence, M.S.; McLeish, K.R.; Dean, W.L.; Arthur, J.M. The calcium-sensing receptor regulates calcium absorption in MDCK cells by inhibition of PMCA. Am. J. Physiol. Renal Physiol. 2001, 280, F815-F822.
11. Ba, J.; Brown, D.; Friedman, P.A. Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport. Am. J. Physiol. Renal Physiol. 2003, 285, F1233-F1243.
12. Hebert, S.C. Bartter syndrome. Curr. Opin. Nephrol. Hypertens. 2003, 12, 527-532.
13. Earm, J.H.; Christensen, B.M.; Frøkiaer, J.; Marples, D.; Han, J.S.; Knepper, M.A.; Nielsen, S. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J. Am. Soc. Nephrol. 1998, 9, 2181-2193.
14. Procino, G.; Mastrofrancesco, L.; Tamma, G.; Lasorsa, D.R.; Ranieri, M.; Stringini, G.; Emma, F.; Svelto, M.; Valenti, G. Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study. PLoS One 2012, 7, e33145.
15. Renkema, K.Y.; Velic, A.; Dijkman, H.B.; Verkaart, S.; van der Kemp, A.W.; Nowik, M.; Timmermans, K.; Doucet, A.; Wagner, C.A.; Bindels, R.J.; Hoenderop, J.G. The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. J. Am. Soc. Nephrol. 2009, 20, 1705-1713.
16. Nyengaard, J.R.; Bendtsen, T.F. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat. Rec. 1992, 232, 194-201.
17. Davies, D.F.; Shock, N.W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J. Clin. Invest. 1950, 29, 496-507.
18. CDC. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb. Mortal. Wkly. Rep. 2007, 56, 161-165.
19. Kuro-o, M.; Matsumura, Y.; Aizawa, H.; Kawaguchi, H.; Suga, T.; Utsugi, T.; Ohyama, Y.; Kurabayashi, M.; Kaname, T.; Kume, E.; et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390, 45-51.
20. Shiraki-Iida, T.; Aizawa, H.; Matsumura, Y.; Sekine, S.; Iida, A.; Anazawa, H.; Nagai, R.; Kuro-o, M.; Nabeshima, Y. Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 1998, 424, 6-10.
21. Kurosu, H.; Ogawa, Y.; Miyoshi, M.; Yamamoto, M.; Nandi, A.; Rosenblatt, K.P.; Baum, M.G.; Schiavi, S.; Hu, M.C.; Moe, O.W.; Kuro-o, M. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006, 281, 6120-6123.
22. Alexander, R.T.; Woudenberg-Vrenken, T.E.; Buurman, J.; Dijkman, H.; van der Eerden, B.C.; van Leeuwen, J.P.; Bindels, R.J.; Hoenderop, J.G. Klotho prevents renal calcium loss. J. Am. Soc. Nephrol. 2009, 20, 2371-2379.
23. Kurosu, H.; Yamamoto, M.; Clark, J.D.; Pastor, J.V.; Nandi, A.; Gurnani, P.; McGuinness, O.P.; Chikuda, H.; Yamaguchi, M.; Kawaguchi, H.; et al. Suppression of aging in mice by the hormone Klotho. Science 2005, 309, 1829-1833.
24. Yamamoto, M.; Clark, J.D.; Pastor, J.V.; Gurnani, P.; Nandi, A.; Kurosu, H.; Miyoshi, M.; Ogawa, Y.; Castrillon, D.H.; Rosenblatt, K.P.; Kuro-o, M. Regulation of oxidative stress by the anti-aging hormone klotho. J. Biol. Chem. 2005, 280, 38029-38034.
25. Maekawa, Y.; Ishikawa, K.; Yasuda, O.; Oguro, R.; Hanasaki, H.; Kida, I.; Takemura, Y.; Ohishi, M.; Katsuya, T.; Rakugi, H. Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine 2009, 35, 341-346.
26. Sugiura, H.; Yoshida, T.; Shiohira, S.; Kohei, J.; Mitobe, M.; Kurosu, H.; Kuro-o, M.; Nitta, K.; Tsuchiya, K. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am. J. Physiol. Renal Physiol. 2012, 302, F1252-F1264.
27. Kim, H.R.; Nam, B.Y.; Kim, D.W.; Kang, M.W.; Han, J.H.; Lee, M.J.; Shin, D.H.; Doh, F.M.; Koo, H.M.; Ko, K.I.; et al. Circulating alpha-Klotho Levels in CKD and Relationship to Progression. Am. J. Kidney Dis. 2013, 61, 899-909.
28. Stubbs, J.R.; He, N.; Idiculla, A.; Gillihan, R.; Liu, S.; David, V.; Hong, Y.; Quarles, L.D. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J. Bone Miner. Res. 2012, 27, 38-46.
29. Tsuruoka, S.; Nishiki, K.; Ioka, T.; Ando, H.; Saito, Y.; Kurabayashi, M.; Nagai, R.; Fujimura, A. Defect in parathyroid-hormone-induced luminal calcium absorption in connecting tubules of Klotho mice. Nephrol. Dial. Transpl. 2006, 21, 2762-2767.
30. Fliser, D.; Kollerits, B.; Neyer, U.; Ankerst, D.P.; Lhotta, K.; Lingenhel, A.; Ritz, E.; Kronenberg, F.; Kuen, E.; Konig, P.; et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007, 18, 2600-2608.
31. Spiegel, D.M.; Brady, K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 2012, 81, 1116-1122.
32. Foley, R.N.; Collins, A.J.; Ishani, A.; Kalra, P.A. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 2008, 156, 556-563.
33. Bolland, M.J.; Grey, A.; Avenell, A.; Gamble, G.D.; Reid, I.R. Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011, 342, d2040.
34. Xiao, Q.; Murphy, R.A.; Houston, D.K.; Harris, T.B.; Chow, W.H.; Park, Y. Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality: The National Institutes of Health-AARP Diet and Health Study. JAMA Intern. Med. 2013, 173, 639-646.
35. Reid, I.R. The acute biochemical effects of four proprietary calcium preparations. Aust. N. Z. J. Med. 1986, 16, 193-197.
36. Michaëlsson, K.; Melhus, H.; Lemming, E.W.; Wolk, A.; Byberg, L. Long term calcium intake and rates of all cause and cardiovascular mortality: Community based prospective longitudinal cohort study. BMJ 2013, 346, f228.
37. Ginde, A.A.; Scragg, R.; Schwartz, R.S.; Camargo, C.A., Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J. Am. Geriatr. Soc. 2009, 57, 1595-1603.
38. Cauley, J.A.; Thompson, D.E.; Ensrud, K.C.; Scott, J.C.; Black, D. Risk of mortality following clinical fractures. Osteoporos Int. 2000, 11, 556-561.
39. Aishah, A.B.; Foo, Y.N. A retrospective study of serum calcium levels in a hospital population in Malaysia. Med. J. Malaysia 1995, 50, 246-249.
40. Hastbacka, J.; Pettila, V. Prevalence and predictive value of ionized hypocalcemia among critically ill patients. Acta Anaesthesiol. Scand. 2003, 47, 1264-1269.
41. Kolb, J.P.; Schilling, A.F.; Bischoff, J.; Novo de Oliveira, A.; Spiro, A.; Hoffmann, M.; Amling, M.; Rueger, J.M.; Lehmann, W. Calcium homeostasis influences radiological fracture healing in postmenopausal women. Arch. Orthop. Trauma Surg. 2012, 133, 187-192.
42. Fatayerji, D.; Mawer, E.B.; Eastell, R. The role of insulin-like growth factor I in age-related changes in calcium homeostasis in men. J. Clin. Endocrinol. Metab. 2000, 85, 4657-4662.
43. Levin, A.; Bakris, G.L.; Molitch, M.; Smulders, M.; Tian, J.; Williams, L.A.; Andress, D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007, 71, 31-38.
44. Vassalotti, J.A.; Uribarri, J.; Chen, S.C.; Li, S.; Wang, C.; Collins, A.J.; Calvo, M.S.; Whaley-Connell, A.T.; McCullough, P.A.; Norris, K.C. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am. J. Kidney Dis. 2008, 51, S56-S68.
45. Markowitz, G.S.; Perazella, M.A. Acute phosphate nephropathy. Kidney Int. 2009, 76, 1027-1034.
46. Gutierrez, O.; Isakova, T.; Rhee, E.; Shah, A.; Holmes, J.; Collerone, G.; Juppner, H.; Wolf, M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 2005, 16, 2205-2215.
47. Moranne, O.; Froissart, M.; Rossert, J.; Gauci, C.; Boffa, J.J.; Haymann, J.P.; M'Rad, M.B.; Jacquot, C.; Houillier, P.; Stengel, B.; Fouqueray, B. Timing of onset of CKD-related metabolic complications. J. Am. Soc. Nephrol. 2009, 20, 164-171.
48. Cannata-Andia, J.B.; Naves-Diaz, M. Phosphorus and survival: Key questions that need answers. J. Am. Soc. Nephrol. 2009, 20, 234-236.
49. Mathew, S.; Tustison, K.S.; Sugatani, T.; Chaudhary, L.R.; Rifas, L.; Hruska, K.A. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J. Am. Soc. Nephrol. 2008, 19, 1092-1105.
50. Kendrick, J.; Chonchol, M. The role of phosphorus in the development and progression of vascular calcification. Am. J. Kidney Dis. 2011, 58, 826-834.
51. Ix, J.H.; De Boer, I.H.; Peralta, C.A.; Adeney, K.L.; Duprez, D.A.; Jenny, N.S.; Siscovick, D.S.; Kestenbaum, B.R. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin. J. Am. Soc. Nephrol. 2009, 4, 609-615.
52. Dhingra, R.; Sullivan, L.M.; Fox, C.S.; Wang, T.J.; D'Agostino, R.B., Sr.; Gaziano, J.M.; Vasan, R.S. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med. 2007, 167, 879-885.
53. Kestenbaum, B.; Sampson, J.N.; Rudser, K.D.; Patterson, D.J.; Seliger, S.L.; Young, B.; Sherrard, D.J.; Andress, D.L. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005, 16, 520-528.
54. Ohnishi, M.; Razzaque, M.S. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010, 24, 3562-3571.
55. Robinson, J.K. Sun exposure, sun protection, and vitamin D. JAMA 2005, 294, 1541-1543.
56. Holick, M.F. The vitamin D epidemic and its health consequences. J. Nutr. 2005, 135, 2739S-2748S.
57. Bosworth, C.R.; Levin, G.; Robinson-Cohen, C.; Hoofnagle, A.N.; Ruzinski, J.; Young, B.; Schwartz, S.M.; Himmelfarb, J.; Kestenbaum, B.; de Boer, I.H. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int. 2012, 82, 693-700.
58. Carlberg, C.; Bendik, I.; Wyss, A.; Meier, E.; Sturzenbecker, L.J.; Grippo, J.F.; Hunziker, W. Two nuclear signalling pathways for vitamin D. Nature 1993, 361, 657-660.
59. Haussler, M.R.; Jurutka, P.W.; Mizwicki, M.; Norman, A.W. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): Genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25, 543-559.
60. Deb, D.K.; Sun, T.; Wong, K.E.; Zhang, Z.; Ning, G.; Zhang, Y.; Kong, J.; Shi, H.; Chang, A.; Li, Y.C. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010, 77, 1000-1009.
61. Vaidya, A.; Forman, J.P.; Williams, J.S. Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. J. Hum. Hypertens. 2011, 25, 672-678.
62. Ohara, I.; Tanimoto, M.; Gohda, T.; Yamazaki, T.; Hagiwara, S.; Murakoshi, M.; Aoki, T.; Toyoda, H.; Ishikawa, Y.; Funabiki, K.; et al. Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp. Nephrol. 2011, 117, e124-e132.
63. Vaidya, A.; Sun, B.; Larson, C.; Forman, J.P.; Williams, J.S. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin II akin to the action of a converting enzyme inhibitor in obese hypertensives: An interventional study. J. Clin. Endocrinol. Metab. 2012, 97, 2456-2465.
64. Martini, L.A.; Wood, R.J. Milk intake and the risk of type 2 diabetes mellitus, hypertension and prostate cancer. Arq. Bras. Endocrinol. Metabol. 2009, 53, 688-694.
65. Gorham, E.D.; Garland, C.F.; Burgi, A.A.; Mohr, S.B.; Zeng, K.; Hofflich, H.; Kim, J.J.; Ricordi, C. Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: A nested case-control study. Diabetologia 2012, 55, 3224-3227.
66. van der Rhee, H.; Coebergh, J.W.; de Vries, E. Is prevention of cancer by sun exposure more than just the effect of vitamin D? A systematic review of epidemiological studies. Eur. J. Cancer 2012, 49, 1422-1436.
67. Bergman, P.; Norlin, A.C.; Hansen, S.; Rekha, R.S.; Agerberth, B.; Bjorkhem-Bergman, L.; Ekstrom, L.; Lindh, J.D.; Andersson, J. Vitamin D3 supplementation in patients with frequent respiratory tract infections: A randomised and double-blind intervention study. BMJ Open 2012, 2, e001663.
68. Balion, C.; Griffith, L.E.; Strifler, L.; Henderson, M.; Patterson, C.; Heckman, G.; Llewellyn, D.J.; Raina, P. Vitamin D, cognition, and dementia: A systematic review and meta-analysis. Neurology 2012, 79, 1397-1405.
69. Mizwicki, M.T.; Menegaz, D.; Zhang, J.; Barrientos-Duran, A.; Tse, S.; Cashman, J.R.; Griffin, P.R.; Fiala, M. Genomic and nongenomic signaling induced by 1alpha,25(OH)2-vitamin D3 promotes the recovery of amyloid-beta phagocytosis by Alzheimer's disease macrophages. J. Alzheimers Dis. 2012, 29, 51-62.
70. Autier, P.; Gandini, S. Vitamin D supplementation and total mortality: A meta-analysis of randomized controlled trials. Arch. Intern. Med. 2007, 167, 1730-1737.
71. de Boer, I.H.; Levin, G.; Robinson-Cohen, C.; Biggs, M.L.; Hoofnagle, A.N.; Siscovick, D.S.; Kestenbaum, B. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: A cohort study. Ann. Intern. Med. 2012, 156, 627-634.
72. Teng, M.; Wolf, M.; Lowrie, E.; Ofsthun, N.; Lazarus, J.M.; Thadhani, R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003, 349, 446-456.
73. Bischoff-Ferrari, H.A.; Shao, A.; Dawson-Hughes, B.; Hathcock, J.; Giovannucci, E.; Willett, W.C. Benefit-risk assessment of vitamin D supplementation. Osteoporos. Int. 2010, 21, 1121-1132.
74. Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266-281.
75. Wang, L.; Song, Y.; Manson, J.E.; Pilz, S.; Marz, W.; Michaelsson, K.; Lundqvist, A.; Jassal, S.K.; Barrett-Connor, E.; Zhang, C.; et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 2012, 5, 819-829.
76. Holick, M.F. Vitamin D status: Measurement, interpretation, and clinical application. Ann. Epidemiol. 2009, 19, 73-78.
77. Forrest, K.Y.; Stuhldreher, W.L. Prevalence and correlates of vitamin D deficiency in US adults. Nutr. Res. 2011, 31, 48-54.
78. Janssen, H.C.; Emmelot-Vonk, M.H.; Verhaar, H.J.; van der Schouw, Y.T. Determinants of vitamin D status in healthy men and women aged 40-80 years. Maturitas 2013, 74, 79-83.
79. MacLaughlin, J.; Holick, M.F. Aging decreases the capacity of human skin to produce vitamin D3. J. Clin. Invest. 1985, 76, 1536-1538.
80. Ebeling, P.R.; Sandgren, M.E.; DiMagno, E.P.; Lane, A.W.; DeLuca, H.F.; Riggs, B.L. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: Relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J. Clin. Endocrinol. Metab. 1992, 75, 176-182.
81. Tsiaras, W.G.; Weinstock, M.A. Factors influencing vitamin D status. Acta Derm. Venereol. 2011, 91, 115-124.
82. Pilz, S.; Iodice, S.; Zittermann, A.; Grant, W.B.; Gandini, S. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am. J. Kidney Dis. 2011, 58, 374-382.
83. Bischoff-Ferrari, H.A.; Willett, W.C.; Orav, E.J.; Lips, P.; Meunier, P.J.; Lyons, R.A.; Flicker, L.; Wark, J.; Jackson, R.D.; Cauley, J.A.; et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 2012, 367, 40-49.
84. de Zeeuw, D.; Agarwal, R.; Amdahl, M.; Audhya, P.; Coyne, D.; Garimella, T.; Parving, H.H.; Pritchett, Y.; Remuzzi, G.; Ritz, E.; Andress, D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010, 376, 1543-1551.
85. Verhave, G.; Siegert, C.E. Role of vitamin D in cardiovascular disease. Neth. J. Med. 2010, 68, 113-118.
86. Rejnmark, L.; Avenell, A.; Masud, T.; Anderson, F.; Meyer, H.E.; Sanders, K.M.; Salovaara, K.; Cooper, C.; Smith, H.E.; Jacobs, E.T.; et al. Vitamin D with calcium reduces mortality: Patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J. Clin. Endocrinol. Metab. 2012, 97, 2670-2681.
87. Shoben, A.B.; Rudser, K.D.; de Boer, I.H.; Young, B.; Kestenbaum, B. Association of oral calcitriol with improved survival in nondialyzed CKD. J. Am. Soc. Nephrol. 2008, 19, 1613-1619.
88. Teng, M.; Wolf, M.; Ofsthun, M.N.; Lazarus, J.M.; Hernan, M.A.; Camargo, C.A., Thadhani, R. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J. Am. Soc. Nephrol. 2005, 16, 1115-1125.
89. Brondum-Jacobsen, P.; Benn, M.; Jensen, G.B.; Nordestgaard, B.G. 25-hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death: Population-based study and meta-analyses of 18 and 17 studies. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2794-2802.
90. Lau, W.L.; Leaf, E.M.; Hu, M.C.; Takeno, M.M.; Kuro-o, M.; Moe, O.W.; Giachelli, C.M. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012, 82, 1261-1270.
91. Segre, G.V.; D'Amour, P.; Hultman, A.; Potts, J.T., Jr. Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. J. Clin. Invest. 1981, 67, 439-448.
92. D'Amour, P.; Lazure, C. Metabolism of radioiodinated carboxy-terminal fragments of bovine parathyroid hormone in normal and anephric rats. Endocrinology 1985, 117, 127-134.
93. Brown, E.M.; Gamba, G.; Riccardi, D.; Lombardi, M.; Butters, R.; Kifor, O.; Sun, A.; Hediger, M.A.; Lytton, J.; Hebert, S.C. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993, 366, 575-580.
94. Egbuna, O.I.; Brown, E.M. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract. Res. Clin. Rheumatol. 2008, 22, 129-148.
95. Ritter, C.S.; Brown, A.J. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J. Mol. Endocrinol. 2011, 46, 63-66.
96. Lavi-Moshayoff, V.; Wasserman, G.; Meir, T.; Silver, J.; Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 2010, 299, F882-F889.
97. Ganong, W.F.; Barrett, K.E. Ganong's Review of Medical Physiology, 24th ed.; Barrett, K.E., Boitano, S., Barman, S.M., Brooks, H.L., Eds.; McGraw-Hill: New York, NY, USA; p. 752.
98. Ferrari, S.L.; Bonjour, J.P.; Rizzoli, R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 2005, 90, 1519-1524.
99. Westerberg, P.A.; Ljunggren, O.; Larsson, T.E.; Wadstrom, J.; Linde, T. Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy. Nephrol. Dial. Transpl. 2010, 25, 4068-4071.
100. Shimada, T.; Hasegawa, H.; Yamazaki, Y.; Muto, T.; Hino, R.; Takeuchi, Y.; Fujita, T.; Nakahara, K.; Fukumoto, S.; Yamashita, T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19, 429-435.
101. Heath, H.; Hodgson, S.F.; Kennedy, M.A. Primary Hyperparathyroidism. N. Engl. J. Med. 1980, 302, 189-193.
102. Block, G.A.; Martin, K.J.; de Francisco, A.L.; Turner, S.A.; Avram, M.M.; Suranyi, M.G.; Hercz, G.; Cunningham, J.; Abu-Alfa, A.K.; Messa, P.; et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 2004, 350, 1516-1525.
103. Urena, P.; Bernard-Poenaru, O.; Cohen-Solal, M.; de Vernejoul, M.C. Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol. Clin. Nephrol. 2002, 57, 261-273.
104. Goodman, W.G.; Ramirez, J.A.; Belin, T.R.; Chon, Y.; Gales, B.; Segre, G.V.; Salusky, I.B. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994, 46, 1160-1166.
105. Yamashita, T.; Yoshioka, M.; Itoh, N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 2000, 277, 494-498.
106. Liu, S.; Zhou, J.; Tang, W.; Jiang, X.; Rowe, D.W.; Quarles, L.D. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E38-E49.
107. Kumar, R. Phosphatonin-a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrol. Dial. Transpl. 1997, 12, 11-13.
108. Canalejo, R.; Canalejo, A.; Martinez-Moreno, J.M.; Rodriguez-Ortiz, M.E.; Estepa, J.C.; Mendoza, F.J.; Munoz-Castaneda, J.R.; Shalhoub, V.; Almaden, Y.; Rodriguez, M. FGF23 fails to inhibit uremic parathyroid glands. J. Am. Soc. Nephrol. 2010, 21, 1125-1135.
109. Stubbs, J.R.; Egwuonwu, S. Is fibroblast growth factor 23 a harbinger of mortality in CKD? Pediatr. Nephrol. 2012, 27, 697-703.
110. Mak, M.P.; da Costa e Silva, V.T.; Martin, R.M.; Lerario, A.M.; Yu, L.; Hoff, P.M.; de Castro, G. Advanced prostate cancer as a cause of oncogenic osteomalacia: An underdiagnosed condition. Support Care Cancer 2012, 20, 2195-2197.
111. Folpe, A.L.; Fanburg-Smith, J.C.; Billings, S.D.; Bisceglia, M.; Bertoni, F.; Cho, J.Y.; Econs, M.J.; Inwards, C.Y.; Jan de Beur, S.M.; Mentzel, T.; et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 2004, 28, 1-30.
112. Bai, X.Y.; Miao, D.; Goltzman, D.; Karaplis, A.C. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem. 2003, 278, 9843-9849.
113. Benet-Pages, A.; Orlik, P.; Strom, T.M.; Lorenz-Depiereux, B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2005, 14, 385-390.
114. Gutierrez, O.M.; Januzzi, J.L.; Isakova, T.; Laliberte, K.; Smith, K.; Collerone, G.; Sarwar, A.; Hoffmann, U.; Coglianese, E.; Christenson, R.; et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119, 2545-2552.
115. Faul, C.; Amaral, A.P.; Oskouei, B.; Hu, M.C.; Sloan, A.; Isakova, T.; Gutierrez, O.M.; Aguillon-Prada, R.; Lincoln, J.; Hare, J.M.; et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 2011, 121, 4393-4408.
116. Gutierrez, O.M.; Mannstadt, M.; Isakova, T.; Rauh-Hain, J.A.; Tamez, H.; Shah, A.; Smith, K.; Lee, H.; Thadhani, R.; Juppner, H.; Wolf, M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008, 359, 584-592.
117. Jean, G.; Terrat, J.C.; Vanel, T.; Hurot, J.M.; Lorriaux, C.; Mayor, B.; Chazot, C. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transpl. 2009, 24, 2792-2796.
118. Hasegawa, H.; Nagano, N.; Urakawa, I.; Yamazaki, Y.; Iijima, K.; Fujita, T.; Yamashita, T.; Fukumoto, S.; Shimada, T. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010, 78, 975-980.
119. Shalhoub, V.; Shatzen, E.M.; Ward, S.C.; Davis, J.; Stevens, J.; Bi, V.; Renshaw, L.; Hawkins, N.; Wang, W.; Chen, C.; et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 2012, 122, 2543-2553.
120. Brown, A.J.; Zhong, M.; Finch, J.; Ritter, C.; McCracken, R.; Morrissey, J.; Slatopolsky, E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am. J. Physiol. 1996, 270, F454-F460.
121. 2+-sensing receptor promotes loss of cancellous bone. Endocrinology 2007, 148, 3156-3163.
122. Pollak, M.R.; Brown, E.M.; Estep, H.L.; McLaine, P.N.; Kifor, O.; Park, J.; Hebert, S.C.; Seidman, C.E.; Seidman, J.G. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat. Genet. 1994, 8, 303-307.
123. Theman, T.A.; Collins, M.T.; Dempster, D.W.; Zhou, H.; Reynolds, J.C.; Brahim, J.S.; Roschger, P.; Klaushofer, K.; Winer, K.K. PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J. Bone Miner. Res. 2009, 24, 964-973.
124. Toke, J.; Czirjak, G.; Patocs, A.; Enyedi, B.; Gergics, P.; Csakvary, V.; Enyedi, P.; Toth, M. Neonatal severe hyperparathyroidism associated with a novel de novo heterozygous R551K inactivating mutation and a heterozygous A986S polymorphism of the calcium-sensing receptor gene. Clin. Endocrinol. (Oxf.) 2007, 67, 385-392.
125. Pollak, M.R.; Brown, E.M.; Chou, Y.H.; Hebert, S.C.; Marx, S.J.; Steinmann, B.; Levi, T.; Seidman, C.E.; Seidman, J.G. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993, 75, 1297-1303.
126. 2+-sensing in cartilage. J. Musculoskelet. Neuronal Interact. 2004, 4, 410-411.
127. Moe, S.; Drueke, T.; Cunningham, J.; Goodman, W.; Martin, K.; Olgaard, K.; Ott, S.; Sprague, S.; Lameire, N.; Eknoyan, G. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006, 69, 1945-1953.
128. Joy, M.S.; Karagiannis, P.C.; Peyerl, F.W. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J. Manag. Care Pharm. 2007, 13, 397-411.
129. Suda, T.; Takahashi, N.; Udagawa, N.; Jimi, E.; Gillespie, M.T.; Martin, T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999, 20, 345-357.
130. Itoh, K.; Udagawa, N.; Matsuzaki, K.; Takami, M.; Amano, H.; Shinki, T.; Ueno, Y.; Takahashi, N.; Suda, T. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J. Bone Miner. Res. 2000, 15, 1766-1775.
131. Kanzawa, M.; Sugimoto, T.; Kanatani, M.; Chihara, K. Involvement of osteoprotegerin/ osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur. J. Endocrinol. 2000, 142, 661-664.
132. Jara, A.; Bover, J.; Felsenfeld, A.J. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int. 1995, 47, 1746-1751.
133. Couttenye, M.M.; D'Haese, P.C.; Deng, J.T.; van Hoof, V.O.; Verpooten, G.A.; de Broe, M.E. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol. Dial. Transpl. 1997, 12, 2144-2150.
134. Cannata-Andia, J.B.; Rodriguez Garcia, M.; Gomez Alonso, C. Osteoporosis and adynamic bone in chronic kidney disease. J. Nephrol. 2013, 26, 73-80.
135. Block, G.A.; Port, F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am. J. Kidney Dis. 2000, 35, 1226-1237.
136. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2009, 113, S1-S130.
137. Kazama, J.J.; Koda, R.; Yamamoto, S.; Narita, I.; Gejyo, F.; Tokumoto, A. Cancellous bone volume is an indicator for trabecular bone connectivity in dialysis patients. Clin. J. Am. Soc. Nephrol. 2010, 5, 292-298.
138. Malluche, H.H.; Monier-Faugere, M.C. Renal osteodystrophy: What's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin. Nephrol. 2006, 65, 235-242.
139. Mac Way, F.; Lessard, M.; Lafage-Proust, M.H. Pathophysiology of chronic kidney disease-mineral and bone disorder. Joint Bone Spine 2012, 79, 544-549.
140. Reeve, J.; Arlot, M.E.; Chavassieux, P.M.; Edouard, C.; Green, J.R.; Hesp, R.; Tellez, M.; Meunier, P.J. The assessment of bone formation and bone resorption in osteoporosis: A comparison between tetracycline-based iliac histomorphometry and whole body 85Sr kinetics. J. Bone Miner. Res. 1987, 2, 479-489.
141. Kiel, D.P.; Kauppila, L.I.; Cupples, L.A.; Hannan, M.T.; O'Donnell, C.J.; Wilson, P.W. Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study. Calcif. Tissue Int. 2001, 68, 271-276.
142. Naves, M.; Rodriguez-Garcia, M.; Diaz-Lopez, J.B.; Gomez-Alonso, C.; Cannata-Andia, J.B. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos. Int. 2008, 19, 1161-1166.
143. Rodriguez Garcia, M.; Naves Diaz, M.; Cannata Andia, J.B. Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence. J. Nephrol. 2005, 18, 458-463.
144. Sigrist, M.; Bungay, P.; Taal, M.W.; McIntyre, C.W. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol. Dial. Transpl. 2006, 21, 707-714.
145. Merjanian, R.; Budoff, M.; Adler, S.; Berman, N.; Mehrotra, R. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int. 2003, 64, 263-271.
146. Goodman, W.G.; Goldin, J.; Kuizon, B.D.; Yoon, C.; Gales, B.; Sider, D.; Wang, Y.; Chung, J.; Emerick, A.; Greaser, L.; et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000, 342, 1478-1483.
147. Stenvinkel, P. Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease. J. Intern. Med. 2010, 268, 456-467.
148. Stenvinkel, P.; Larsson, T.E. Chronic Kidney Disease: A Clinical Model of Premature Aging Am. J. Kidney Dis. 2013, in press. Avaiable online: http://www.sciencedirect.com/science/ article/pii/S0272638612015922 (accessed on 15 May 2013).
149. Reynolds, J.L.; Joannides, A.J.; Skepper, J.N.; McNair, R.; Schurgers, L.J.; Proudfoot, D.; Jahnen-Dechent, W.; Weissberg, P.L.; Shanahan, C.M. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 2004, 15, 2857-2867.
150. Lim, K.; Lu, T.S.; Molostvov, G.; Lee, C.; Lam, F.T.; Zehnder, D.; Hsiao, L.L. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012, 125, 2243-2255.
151. Sigrist, M.K.; Taal, M.W.; Bungay, P.; McIntyre, C.W. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2007, 2, 1241-1248.
152. Floege, J.; Kim, J.; Ireland, E.; Chazot, C.; Drueke, T.; de Francisco, A.; Kronenberg, F.; Marcelli, D.; Passlick-Deetjen, J.; Schernthaner, G.; et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol. Dial. Transpl. 2011, 26, 1948-1955.
153. Block, G.A.; Wheeler, D.C.; Persky, M.S.; Kestenbaum, B.; Ketteler, M.; Spiegel, D.M.; Allison, M.A.; Asplin, J.; Smits, G.; Hoofnagle, A.N.; et al. Effects of phosphate binders in moderate CKD. J. Am. Soc. Nephrol. 2012, 23, 1407-1415.
154. Chue, C.D.; Townend, J.N.; Moody, W.E.; Zehnder, D.; Wall, N.A.; Harper, L.; Edwards, N.C.; Steeds, R.P.; Ferro, C.J. Cardiovascular Effects of Sevelamer in Stage 3 CKD. J. Am. Soc. Nephrol. 2013, 24, 842-852.
155. Andress, D.L.; Coyne, D.W.; Kalantar-Zadeh, K.; Molitch, M.E.; Zangeneh, F.; Sprague, S.M. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr. Pract. 2008, 14, 18-27.
156. Cunningham, J.; Danese, M.; Olson, K.; Klassen, P.; Chertow, G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005, 68, 1793-1800.
157. Chertow, G.M.; Block, G.A.; Correa-Rotter, R.; Drueke, T.B.; Floege, J.; Goodman, W.G.; Herzog, C.A.; Kubo, Y.; London, G.M.; Mahaffey, K.W.; et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 2012, 367, 2482-2494.